Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Angion Biomedica's share price for the quarter that ended in Mar. 2023 was $5.8. Angion Biomedica's Shares Outstanding (EOP) for the quarter that ended in Mar. 2023 was 30.11 Mil. Therefore, Angion Biomedica's market cap for the quarter that ended in Mar. 2023 was $174.66 Mil.
Angion Biomedica's quarterly market cap
declined
from Sep. 2022 ($277.05 Mil) to Dec. 2022 ($244.41 Mil) and
declined
from Dec. 2022 ($244.41 Mil) to Mar. 2023 ($174.66 Mil).
Angion Biomedica's annual market cap
increased
from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($868.74 Mil) but then
declined
from Dec. 2021 ($868.74 Mil) to Dec. 2022 ($244.41 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Angion Biomedica's Enterprise Value for Today is $272.22 Mil.
Angion Biomedica Market Cap Historical Data
The historical data trend for Angion Biomedica's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Angion Biomedica's Market Cap
For the Biotechnology subindustry, Angion Biomedica's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Angion Biomedica's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Angion Biomedica's Market Cap distribution charts can be found below:
* The bar in red indicates where Angion Biomedica's Market Cap falls into.
Angion Biomedica Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Angion Biomedica's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Angion Biomedica (NAS:ANGN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Angion Biomedica Market Cap Related Terms
Thank you for viewing the detailed overview of Angion Biomedica's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Angion Biomedica (Angion Biomedica) Business Description
Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with a primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading to ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANGN has been successfully added to your 